Plusbiome is developing a biotechnology platform that focuses on the interaction between the gut microbiome and the immune system to enhance anti-cancer immunity. By validating these pathways, the company aims to improve treatment outcomes for cancer patients through targeted therapeutic interventions.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often fail to fully harness the body's immune system to fight tumors effectively. The complex interplay between the gut microbiome and the immune system remains largely unexploited in cancer therapy, limiting the potential for more effective and targeted interventions.
Solution
Plusbiome is developing a biotechnology platform that leverages the interaction between the gut microbiome and the immune system to enhance anti-cancer immunity. The company is validating pathways between the gut microbiome and the immune system to selectively regulate these mechanisms and drive effective anti-cancer immunity. This approach aims to improve treatment outcomes for cancer patients by developing a new class of anticancer medicines. Plusbiome's portfolio of assets is being validated in pre-clinical studies, focusing on the immune conditioning of the microbiome in cancer therapies.
Target Audience
The primary target audience includes cancer patients, oncologists, and researchers focused on immuno-oncology and microbiome-based therapies.
Features
- Focus on the interaction between the gut microbiome and the immune system.
- Development of a new class of anticancer medicines.
- Validation of pathways between the gut microbiome and the immune system.
- Pre-clinical studies to validate the company's portfolio of assets.
- Selective regulation of mechanisms to drive effective anti-cancer immunity.